HT-61

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H24N2O
Molecular Weight	380.4816
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(C=C(OC3=CC=CC=C3)C=C2)C4=C1CCN4CCC5=CC=CC=C5

InChI

InChIKey=XCZMUTGHJBFKPM-UHFFFAOYSA-N

InChI=1S/C26H24N2O/c1-19-23-15-17-28(16-14-20-8-4-2-5-9-20)26(23)24-18-22(12-13-25(24)27-19)29-21-10-6-3-7-11-21/h2-13,18H,14-17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C26H24N2O
Molecular Weight	380.4816
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:39:34 GMT 2025` Edited by `admin` on `Tue Apr 01 16:39:34 GMT 2025`
Record UNII	ZE7QPY4258
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1H-PYRROLO(3,2-C)QUINOLINE, 2,3-DIHYDRO-4-METHYL-8-PHENOXY-1-(2-PHENYLETHYL)-

Preferred Name

English

HT-61

Code

English

HT61

Code

English

4-METHYL-1-(2-PHENYLETHYL)-8-PHENOXY-2,3-DIHYDRO-1H-PYRROLO(3,2-C)QUINOLONE

Systematic Name

English

4-METHYL-1-PHENETHYL-8-PHENOXY-2,3-DIHYDROPYRROLO(3,2-C)QUINOLINE

Systematic Name

English

Code System Code Type Description

FDA UNII

ZE7QPY4258

Created by admin on Tue Apr 01 16:39:34 GMT 2025 , Edited by admin on Tue Apr 01 16:39:34 GMT 2025

PRIMARY

PUBCHEM

16727326

Created by admin on Tue Apr 01 16:39:34 GMT 2025 , Edited by admin on Tue Apr 01 16:39:34 GMT 2025

PRIMARY

SMS_ID

300000051762

Created by admin on Tue Apr 01 16:39:34 GMT 2025 , Edited by admin on Tue Apr 01 16:39:34 GMT 2025

PRIMARY

CAS

936622-80-9

Created by admin on Tue Apr 01 16:39:34 GMT 2025 , Edited by admin on Tue Apr 01 16:39:34 GMT 2025

PRIMARY

Related Record Type Details


					ZE7QPY4258

HT-61

ACTIVE MOIETY

Comments:

Drug: HT 61(Primary), Chlorhexidine/neomycin, Mupirocin; Indication: Staphylococcal infections; Focus: Therapeutic Use; Sponsor: Helperby Therapeutics; Most Recent Events: 10 May 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record., 14 Mar 2012 New trial record


					ZE7QPY4258

HT-61

ACTIVE MOIETY

Comments:

Originator: Helperby Therapeutics; Class: Antibacterial, Quinolone, Small molecule; Mechanism of Action: Cell membrane modulator, Cell wall inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase III for Staphylococcal infections; Most Recent Events: 10 Jun 2015 Phase III development is ongoing in the United Kingdom, 04 Dec 2013 Phase-III development is ongoing in UK, 21 Feb 2012 Helperby Therapeutics initiates enrolment in a phase II trial for Staphylococcal infections in United Kingdom (EudraCT2011-002438-38)


					ZE7QPY4258

HT-61

ACTIVE MOIETY

Comments:

Results: Using the fractional inhibitory concentration index, no interaction was seen in both MSSA and MRSA for the pair HT61 and gentamicin or the pair HT61 and neomycin. Synergism was seen for 65% of both MSSA and MRSA when HT61 was combined with chlorhexidine. There was also no interaction between HT61 and mupirocin. Timekill analysis demonstrated significant synergistic activities when a low level of HT61 was combined with neomycin, gentamicin or chlorhexidine. The effect was more dramatic against non-multiplying bacteria against which the antimicrobials used were inactive on their own. Significant synergistic effects were also seen on mouse infected skin.